Literature DB >> 15538260

Graft function after kidney transplantation from non-heartbeating donors according to maastricht category.

Muhammad A Gok1, John F Asher, Brian K Shenton, David Rix, Naeem A Soomro, Bryon C Jaques, Derek M Manas, David Talbot.   

Abstract

PURPOSE: Donor shortages have led to some groups using alternative sources such as non-heartbeating donors (NHBDs). Kidneys from NHBDs suffer from warm ischemia at cardiac arrest which is reflected by acute tubular necrosis of the allograft, resulting in a period of delayed graft function. NHBDs are categorized by the circumstances surrounding the agonal events of death which reflect differences in the likelihood of ischemic injury to the kidney. In this study we determined the impact of ischemic injury on the renal function of kidneys procured from different categories of NHBDs.
MATERIALS AND METHODS: From 1998 to 2003, 144 kidneys were procured from 72 NHBDs resulting in 93 transplants characterized into Maastricht categories II, III and IV NHBD renal transplants. Renal function after transplant was evaluated from the last dialysis until discharge from hospital, and then at 3 monthly intervals thereafter.
RESULTS: Primary warm ischemic time is more prolonged in the uncontrolled donor (category II) than controlled donor (category III greater than IV). Delayed graft function occurs more frequently (Maastricht category II 83.8%, III 67.4% and IV 0%, ANOVA p <0.05) and the return to normal function is more prolonged in uncontrolled donors. This is illustrated by the greater incidence of acute tubular necrosis (Maastricht category II 81.1%, III 65.2% and IV 50.0%, ANOVA p = nonsignificant) in the kidney allograft. There was no difference in year 1 allograft survival (Maastricht category II 83.9%, III 92.5% and IV 100%, ANOVA p = nonsignificant).
CONCLUSIONS: Early graft function is poorest in kidneys derived from Maastricht category II donors and best in category IV with III in-between. However, after 3 months the function of kidneys from all donors is the same.

Entities:  

Mesh:

Year:  2004        PMID: 15538260     DOI: 10.1097/01.ju.0000145128.00771.14

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Current status and recent advances of liver transplantation from donation after cardiac death.

Authors:  M Thamara Pr Perera; Simon R Bramhall
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  Renal artery stenosis: a classic presentation, a rare cause...

Authors:  Karen J Woittiez; Marjolijn van Buren; Jozef Kesecioglu
Journal:  BMJ Case Rep       Date:  2012-08-13

3.  A Prospective Randomised Paired Trial of Sirolimus versus Tacrolimus as Primary Immunosuppression following Non-Heart Beating Donor Kidney Transplantation.

Authors:  John Asher; Nikhil Vasdev; Hugh Wyrley-Birch; Colin Wilson; Naeem Soomro; David Rix; Bryon Jaques; Derek Manas; Nicholas Torpey; David Talbot
Journal:  Curr Urol       Date:  2014-08-20

4.  Kidney retrieval after sudden out of hospital refractory cardiac arrest: a cohort of uncontrolled non heart beating donors.

Authors:  Fabienne Fieux; Marie-Reine Losser; Eric Bourgeois; Francine Bonnet; Olivier Marie; François Gaudez; Imad Abboud; Jean-Luc Donay; France Roussin; François Mourey; Frédéric Adnet; Laurent Jacob
Journal:  Crit Care       Date:  2009-08-28       Impact factor: 9.097

Review 5.  Non heart-beating donors in England.

Authors:  Eleazar Chaib
Journal:  Clinics (Sao Paulo)       Date:  2008-02       Impact factor: 2.365

6.  Similar 5-Year Estimated Glomerular Filtration Rate Between Kidney Transplants From Uncontrolled and Controlled Donors After Circulatory Death-A Dutch Cohort Study.

Authors:  Hessel Peters-Sengers; Jaap J Homan van der Heide; Martin B A Heemskerk; Ineke J M Ten Berge; Fred C W Ultee; Mirza M Idu; Michiel G H Betjes; Arjan D van Zuilen; Maarten H L Christiaans; Luuk H Hilbrands; Aiko P J de Vries; Azam S Nurmohamed; Stefan P Berger; Frederike J Bemelman
Journal:  Transplantation       Date:  2017-06       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.